Prague Med. Rep. 2023, 124, 216-229
https://doi.org/10.14712/23362936.2023.17
Effects of Cannabidiol in Inflammation: A Review of Pre-clinical and Clinical Findings
References
1. , B., Taylor, D. M., Bourke, E., Pollack, K., Foster, L., Ching, M., Wong, A. (2021) The CANBACK trial: A randomised, controlled clinical trial of oral cannabidiol for people presenting to the emergency department with acute low back pain. Med. J. Aust. 214, 370–375.
<https://doi.org/10.5694/mja2.51014>
2. , F., Aviello, G., Romano, B., Orlando, P., Capasso, R., Maiello, F., Guadagno, F., Petrosino, S., Capasso, F., Di Marzo, V., Izzo, A. A. (2009) Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J. Mol. Med. (Berl.) 87, 1111–1121.
<https://doi.org/10.1007/s00109-009-0512-x>
3. , V., Wang, B., Gerasymchuk, M., Fiselier, A., Kovalchuk, O., Kovalchuk, I. (2022) Use of cannabis and cannabinoids for treatment of cancer. Cancers 14, 5142.
<https://doi.org/10.3390/cancers14205142>
4. , P., Laguna, J., Allender, J., Snider, S., Stern, L., Sandyk, R., Kennedy, K., Schram, K. (1991) Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav. 40, 701–708.
<https://doi.org/10.1016/0091-3057(91)90386-G>
5. , D. G., Tasker, C., Theophilidou, E., Lund, J. N., O’Sullivan, S. E. (2017) Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon. Clin. Sci. (Lond.) 131, 2611–2626.
<https://doi.org/10.1042/CS20171288>
6. , L., Ligresti, A., Moriello, A. S., Allara, M., Bisogno, T., Petrosino, S., Stott, C. G., Di Marzo, V. (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br. J. Pharmacol. 163, 1479–1494.
<https://doi.org/10.1111/j.1476-5381.2010.01166.x>
7. , M. J., Maisto, S. A., Gilmour, C. E., McGuire, L., Tarvin, E., Moskal, D. (2022) The effects of cannabidiol and analgesic expectancies on experimental pain reactivity in healthy adults: A balanced placebo design trial. Exp. Clin. Psychopharmacol. 30, 536–546.
<https://doi.org/10.1037/pha0000465>
8. European Medicines Agency (2023) Epidyolex. Accessed March 27, 2023. Available at: https://www.ema.europa.eu/en/documents/product-information/epidyolex-epar-product-information_en.pdf
9. , L. J., Boesch, J. M., Frye, C. W., Schwark, W. S., Mann, S., Wolfe, L., Brown, H., Berthelsen, E. S., Wakshlag, J. J. (2018) Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front. Vet. Sci. 5, 165.
<https://doi.org/10.3389/fvets.2018.00165>
10. , A., Khan, I. A., Abdelaal, M. S., Banerjee, S., Sharkey, P. F., Lonner, J. H. (2022) Topical cannabidiol (CBD) after total knee arthroplasty does not decrease pain or opioid use: A prospective randomized double-blinded placebo-controlled trial. J. Arthroplasty 37, 1763–1770.
<https://doi.org/10.1016/j.arth.2022.03.081>
11. , D. C., Zhang, L. P., Ma, F., Abshire, S. M., McIlwrath, S. L., Stinchcomb, A. L., Westlund, K. N. (2016) Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur. J. Pain 20, 936–948.
<https://doi.org/10.1002/ejp.818>
12. , J. T., Forster, G. L., Stephens, K. L., Cottler, P. S., Timko, M. P., DeGeorge, B. R. Jr. (2022) A randomized controlled trial of topical cannabidiol for the treatment of thumb basal joint arthritis. J. Hand Surg. Am. 47, 611–620.
<https://doi.org/10.1016/j.jhsa.2022.03.002>
13. , M. A. (2007) Human cannabinoid pharmacokinetics. Chem. Biodivers. 4, 1770–1804.
<https://doi.org/10.1002/cbdv.200790152>
14. , K. A., Ratcliffe, S. H., Barrett, D. A., Thomas, E. L., Stott, C., Bell, J. D., O’Sullivan, S. E., Tan, G. D. (2016) Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39, 1777–1786.
<https://doi.org/10.2337/dc16-0650>
15. James, S. (2020) A Clinician’s Guide to Cannabinoid Science, Chapter 9: Cannabinoids and Inflammation and Autoimmune Disorders. Cambridge University Press, Cambridge.
16. , J. M., Molleman, A., Pertwee, R. G., Parsons, M. E. (2010) The effects of delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br. J. Pharmacol. 160, 712–723.
<https://doi.org/10.1111/j.1476-5381.2010.00791.x>
17. Jelinek, P., Rousarova, J., Rysanek, P., Jezkova, M., Havlujova, T., Pozniak, J., Kozlik, P., Krizek, T., Kucera, T., Sima, M., Slanar, O., Soos, M. (2022) Application of oil-in-water cannabidiol emulsion for the treatment of rheumatoid arthritis. Cannabis Cannabinoid Res. (Epub ahead of print)
18. , R. B., Bagher, A. M., Kelly, M. E. M., Denovan-Wright, E. M. (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172, 4790–4805.
<https://doi.org/10.1111/bph.13250>
19. , C., Fisher, N. B., Tugwell, B., Szczesniak, A., Kelly, M., Zhou, J. (2016) Experimental cannabidiol treatment reduces early pancreatic inflammation in type 1 diabetes. Clin. Hemorheol. Microcirc. 64, 655–662.
<https://doi.org/10.3233/CH-168021>
20. , T., Tingting, R., Zurmahr, J., Classen, T., Schneider, M., Pongratz, G. (2020) Cannabidiol (CBD): A killer for inflammatory rheumatoid arthritis synovial fibroblasts. Cell Death Dis. 11, 714.
<https://doi.org/10.1038/s41419-020-02892-1>
21. , C. J., Galettis, P., Schneider, J. (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 84, 2477–2482.
<https://doi.org/10.1111/bcp.13710>
22. , A. M., Gallily, R., Sumariwalla, P. F., Malik, A. S., Andreakos, E., Mechoulam, R., Feldmann, M. (2000) The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 97, 9561–9566.
<https://doi.org/10.1073/pnas.160105897>
23. , R., Parker, L. A., Gallily, R. (2002) Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol. 42, 11s–19s.
<https://doi.org/10.1002/j.1552-4604.2002.tb05998.x>
24. , P., Reggio, P. H. (2019) CBD: A new hope? ACS Med. Chem. Lett. 10, 694–695.
<https://doi.org/10.1021/acsmedchemlett.9b00127>
25. , P., Hurst, D. P., Reggio, P. H. (2017) Molecular targets of the phytocannabinoids: A complex picture. Prog. Chem. Org. Nat. Prod. 103, 103–131.
26. Mucke, M., Phillips, T., Radbruch, L., Petzke, F., Hauser, W. (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 3, CD012182.
27. , T., Mechulam, R., Marii, A., Gabay, G., Stein, A., Bronshtain, M., Laish, I., Benjaminov, F., Konikoff, F. M. (2017) Low-dose cannabidiol is safe but not effective in the treatment for Crohn’s disease, a randomized controlled trial. Dig. Dis. Sci. 62, 1615–1620.
<https://doi.org/10.1007/s10620-017-4540-z>
28. , P., Pandey, R., Rieder, S. A., Hegde, V. L., Nagarkatti, M. (2009) Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem. 1, 1333–1349.
<https://doi.org/10.4155/fmc.09.93>
29. , G., Grotenhermen, F., Zuardi, A. W., Crippa, J. A. S. (2017) A conversion of oral cannabidiol to delta9-tetrahydrocannabinol seems not to occur in humans. Cannabis Cannabinoid Res. 2, 81–86.
<https://doi.org/10.1089/can.2017.0009>
30. , J. M., Kaplan, B. L. F. (2020) Immune responses regulated by cannabidiol. Cannabis Cannabinoid Res. 5, 12–31.
<https://doi.org/10.1089/can.2018.0073>
31. , A., Lindgren, J. E., Andersson, S., Agurell, S., Gillespie, H., Hollister, L. E. (1986) Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed. Environ. Mass Spectrom. 13, 77–83.
<https://doi.org/10.1002/bms.1200130206>
32. , P., Kogan, N. M., Mechoulam, R. (2020) Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659.
<https://doi.org/10.1146/annurev-pharmtox-010818-021441>
33. , F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., Corsi, L. (2018) Cannabis sativa L. and nonpsychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. Biomed Res. Int. 2018, 1691428.
<https://doi.org/10.1155/2018/1691428>
34. , R. G. (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 76, 1307–1324.
<https://doi.org/10.1016/j.lfs.2004.10.025>
35. , H. T., O’Brien, M., McDougall, J. J. (2017) Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain 158, 2442–2451.
<https://doi.org/10.1097/j.pain.0000000000001052>
36. , S. H., Hasko, J., Skuba, A., Fan, S., Dykstra, H., McCormick, R., Reichenbach, N., Krizbai, I., Mahadevan, A., Zhang, M., Tuma, R., Son, Y. J., Persidsky, Y. (2012) Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J. Neurosci. 32, 4004–4016.
<https://doi.org/10.1523/JNEUROSCI.4628-11.2012>
37. , E. B., Guy, G. W., Robson, P. J. (2007) Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem. Biodivers. 4, 1729–1743.
<https://doi.org/10.1002/cbdv.200790150>
38. , T., Zurbriggen, L., Dieterle, M., Mauermann, E., Frei, P., Mercer-Chalmers-Bender, K., Ruppen, W. (2022) Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). Pain 163, e62–e71.
<https://doi.org/10.1097/j.pain.0000000000002310>
39. , E., Lorenzini, S., Garcia-Gonzalez, E., Maggio, R., Lazzerini, P. E., Capecchi, P. L., Balistreri, E., Spreafico, A., Niccolini, S., Pompella, G., Natale, M. R., Guideri, F., Laghi Pasini, F., Galeazzi, M., Marcolongo, R. (2008) Inhibitory effect of synthetic cannabinoids on cytokine production in rheumatoid fibroblast-like synoviocytes. Clin. Exp. Rheumatol. 26, 574–581.
40. , N., Haroutounian, S., Hohmann, A. G., Krane, E., Liao, J., Macleod, M., Segelcke, D., Sena, C., Thomas, J., Vollert, J., Wever, K., Alaverdyan, H., Barakat, A., Barthlow, T., Bozer, A. L. H., Davidson, A., Diaz-delCastillo, M., Dolgorukova, A., Ferdousi, M. I., Healy, C., Hong, S., Hopkins, M., James, A., Leake, H. B., Malewicz, N. M., Mansfield, M., Mardon, A. K., Mattimoe, D., McLoone, D. P., Noes-Holt, G., Pogatzki-Zahn, E. M., Power, E., Pradier, B., Romanos-Sirakis, E., Segelcke, A., Vinagre, R. Yanes, J. A., Zhang, J., Zhang, X. Y., Finn, D. P., Rice, A. S. C. (2021) Systematic review and meta-analysis of cannabinoids, cannabis-based medicines, and endocannabinoid system modulators tested for antinociceptive effects in animal models of injury-related or pathological persistent pain. Pain 162, S26–S44.
<https://doi.org/10.1097/j.pain.0000000000002269>
41. , I., Hanus, L. (2016) Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res. 1, 90–101.
<https://doi.org/10.1089/can.2015.0012>
42. , A. B., de Roos, N. M., Majait, S., Witteman, B. J. M., Witkamp, R. F. (2022) Effects of cannabidiol chewing gum on perceived pain and well-being of irritable bowel syndrome patients: A placebo-controlled crossover exploratory intervention study with symptom-driven dosing. Cannabis Cannabinoid Res. 7, 436–444.
<https://doi.org/10.1089/can.2020.0087>
43. , J., Dreyer, L., Petersen, K. K., Arendt-Nielsen, L., Duch, K. S., Kristensen, S. (2022) Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: A randomized, double-blind, placebo-controlled trial. Pain 163, 1206–1214.
<https://doi.org/10.1097/j.pain.0000000000002466>
44. , C. D., Wesson, S., Konduri, V., Hofferek, C. J., Vazquez-Perez, J., Blair, E., Dunner, K. Jr., Salimpour, P., Decker, W. K., Halpert, M. M. (2020) A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain 161, 2191–2202.
<https://doi.org/10.1097/j.pain.0000000000001896>
45. , D. T., Robson, P., House, H., Makela, P., Aram, J. (2003) A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin. Rehabil. 17, 21–29.
<https://doi.org/10.1191/0269215503cr581oa>
46. , Y., Wang, X., Yang, Y., Quan, Q., Huo, T., Yang, S., Ju, R., An, Q. (2022) Comparison of the in vitro anti-inflammatory effect of cannabidiol to dexamethasone. Clin. Cosmet. Investig. Dermatol. 15, 1959–1967.
<https://doi.org/10.2147/CCID.S378798>
47. , L., Stott, C. G., Jones, N. A., Wright, S. (2017) Cannabidiol does not convert to Δ9-tetrahydrocannabinol in an in vivo animal model. Cannabis Cannabinoid Res. 2, 282–287.
<https://doi.org/10.1089/can.2017.0032>
48. , D. H., Cullen, B. D., Tang, M., Fang, Y. (2020) The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr. Pharm. Biotechnol. 21, 390–402.
<https://doi.org/10.2174/1389201020666191202111534>
49. , R. B., Burstein, S. H. (2016) Cannabinoids, inflammation, and fibrosis. FASEB J. 30, 3682–3689.
<https://doi.org/10.1096/fj.201600646R>
